Formycon AG (FYB)

Overview

Formycon AG, originally founded as Nanohale AG in 1999 and undergoing a name change to its current identity in 2012, is a biopharmaceutical company headquartered in Planegg, Germany. Specializing in the development and marketing of biosimilar products, Formycon has a robust footprint in Germany and Switzerland. The company primarily focuses on creating biosimilars for a range of complex biologic medicines, covering treatments for age-related macular degeneration, chronic inflammatory diseases, cancer, and viral infections like COVID-19. Its strategic position in the biosimilar market is highlighted by its commitment to offering effective, accessible, and cost-efficient alternatives to original biopharmaceutical products.

Products and Services

• FYB201 - Ranivisio, ONGAVIA, CIMERLI: Formycon's biosimilar candidate for Lucentis, FYB201, is marketed under the names Ranivisio, ONGAVIA, and CIMERLI. It is designed for the treatment of neovascular age-related macular degeneration (AMD) and other serious retinal diseases, including diabetic macular edema and myopic choroidal neovascularization. This product aims to deliver a high-quality, biosimilar option for managing conditions leading to severe vision loss.
• FYB202: A biosimilar candidate for Stelara, FYB202 is in the final stages of clinical development. This biosimilar aims to provide treatment for chronic inflammatory conditions, such as moderate to severe psoriasis, Crohn's disease, and ulcerative colitis. Completing Phase III clinical trials, FYB202 demonstrates Formycon's capabilities in addressing autoimmune diseases with a viable biosimilar solution.
• FYB203: In Phase III clinical trials, FYB203 is a biosimilar candidate for Eylea, targeting neovascular age-related macular degeneration and similar serious retinal diseases. By developing FYB203, Formycon extends its portfolio in the ophthalmic disease sector, offering an alternative to existing treatments for AMD and other eye conditions that threaten eyesight.
• FYB206: A biosimilar candidate for Keytruda, FYB206 is Formycon's venture into cancer treatment. Keytruda, a well-known immuno-oncology drug, has shown effectiveness in treating various types of cancer. With FYB206, Formycon aims to contribute to the oncology sector by providing a biosimilar that could increase treatment accessibility and affordability for cancer patients.
• FYB207: Reflecting Formycon's adaptability to global health needs, FYB207 is in development as a SARS-CoV-2 blocker. This antiviral drug is aimed at treating COVID-19 and represents the company's foray into infectious disease treatment with a focus on the ongoing challenges posed by the pandemic. FYB207 exemplifies Formycon's commitment to leveraging its biosimilar expertise for broad public health applications.